Highlights d SERINC5 antagonism is a fundamental property of primate lentiviral Nef proteins d Increases in Nef-mediated anti-SERINC5 activity preceded the emergence of HIV-1 d HIV-1 Nefs are more potent SERINC5 antagonists than HIV-2 Nefs d
In Brief
SERINC5 is a restriction factor that impairs the infectivity of retroviral particles. Heigele et al. show that the potency of SERINC5 antagonism by the accessory viral protein Nef correlates with the prevalence of corresponding SIVs in their respective wild-living hosts, suggesting that SERINC5 is a potential determinant of viral spread.
INTRODUCTION
The accessory protein Nef of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) is required for efficient viral replication and substantially accelerates disease progression in vivo (Kestler et al., 1991; Deacon et al., 1995; Kirchhoff et al., 1995) . Despite its small size of about 27-35 kDa, Nef performs a striking number of functions, including downmodulation of the CD4 receptor and MHC class I molecules from the cell surface and stimulation of viral replication in CD4+ T cells (Arhel and Kirchhoff, 2009; Pawlak and Dikeakos, 2015) . Although these activities are conserved among primate lentiviral Nef proteins, important differences also exist. For example, the Nef proteins of HIV-2 and most SIVs downmodulate CD3 to suppress T cell activation, while the Nef proteins of HIV-1 and its vpu-containing simian precursors lost this function . Moreover, most SIVs and the O group of HIV-1 use Nef to antagonize the restriction factor tetherin that inhibits the release of budding virions, while pandemic HIV-1 M strains use Vpu for the same function (Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009; Kluge et al., 2014) . Thus, Nef acts throughout the replication cycle and promotes viral immune evasion and replication using a remarkable combination of diverse functions.
The ability of Nef to enhance the infectivity of HIV-1 particles was noted more than 20 years ago (Chowers et al., 1994; Miller et al., 1994) , but the underlying mechanisms remained controversial. Nef-mediated downmodulation of CD4 increases the amount of Env glycoprotein in virus particles, and it was thus proposed that this enhances viral infectivity (Lama et al., 1999; Argañ araz et al., 2003) . However, Nef also enhanced the infectivity of virus particles generated in CD4-negative producer cells, which was explained by reduced proteasomal degradation of virions (Qi and Aiken, 2007) , increased cholesterol content of viral particles (Zheng et al., 2003) , or enhanced transport of the viral preintegration complex through the cortical actin network (Campbell et al., 2004) . The effect of Nef on HIV-1 infectivity was also shown to depend on the envelope glycoprotein (Env) since VSV-G-pseudotyped particles were not affected (Aiken, 1997) . Furthermore, Nef affects the infectivity of neutralization-sensitive CXCR4-tropic Env containing viruses more severely than those carrying neutralization-resistant CCR5-tropic Envs (Usami and Gö ttlinger, 2013) . Another puzzling finding was that the glycosylated Gag protein (glycoGag) of murine leukemia virus (MLV) enhances HIV-1 infectivity in a manner very similar to Nef (Pizzato, 2010) .
These seemingly discrepant results were recently reconciled by two elegant studies, which showed that Nef-mediated downmodulation of the multipass transmembrane proteins serine incorporator 3 and 5 (SERINC3 and SERINC5) from the cell surface prevents their incorporation into viral particles and thus increases virion infectivity (Rosa et al., 2015; Usami et al., 2015) . Rosa et al. (2015) further demonstrated that the Nef proteins of SIVs infecting macaques and African green monkeys are capable of counteracting human SERINC5. Here, we examined the anti-SERINC5 activity of Nef proteins representing nearly the entire spectrum of primate lentiviruses to examine the role of this restriction factor in viral transmission within and between primate species. Our results show that Nef-mediated SERINC5 antagonism is largely species independent and suggest that the potency of this counteraction may determine, at least in part, the ability of primate lentiviruses to spread within their natural hosts.
RESULTS

SERINC5 Inhibits Primary HIV-1 and SIV Strains More Efficiently than SERINC3
Although SERINC5 has been reported to impair HIV-1 infectivity to a greater extent than SERINC3 (Rosa et al., 2015; Usami et al., 2015) , these data were mainly derived using the T cell line adapted HIV-1 NL4-3 molecular clone. We thus examined the ability of SERINC3 and SERINC5 to inhibit six HIV-1 and SIV strains containing either wild-type (WT) or defective nef genes. Two days post-transfection, infectious virus yield was determined by infection of TZM-bl cells. The susceptibility to SERINC5 and SERINC3 restriction varied among the different HIV-1 and SIV strains ( Figures 1A and S1A ). SERINC5 reduced the infectivity of WT HIV-1 strains by 50% (NL4-3) to 90% (CH167) and that of the nef-defective derivatives by 80% to 98%, while SERINC3 was generally poorly effective ( Figure 1A , left). On average, transient SERINC5 expression reduced HIV-1 infectious titers by 90% in the absence of Nef, while SERINC3 achieved only a 20% reduction ( Figure 1A , right). Intact nef genes (Figure 1A) or coexpression of Nef in trans ( Figure S1B ) markedly counteracted SERINC5 inhibition. Intact nef genes also increased infectious virus yield in HEK239T cells in the absence of exogenous SERINC5 ( Figure 1A ), possibly because these cells express low levels of endogenous SERINC5 (Usami et al., 2015) . Because SERINC3 generally reduced infectious HIV-1 yields only minimally, we focused on SERINC5 in subsequent experiments. SERINC5 Is Counteracted by Nef, but Not by Vpu or Vpr Nef shows functional redundancy with Vpu in modulating cellular receptors, such as CD4, CD1d, and tetraspanins (Haller et al., 2014) , and the accessory protein Vpr has also been implicated in enhancing viral infectivity (Ueno et al., 2003) . To determine the effect of all three accessory proteins on viral susceptibility to SERINC5 inhibition, we generated vpu-, vpr-, and nef-defective derivatives of HIV-1 infectious molecular clones (IMCs) representing two clade B and four clade C strains ( Figure 1B) . These included transmitted founder HIV-1 strains (CH058, CH198, ZM246), as well as viruses predominant during chronic infection (STCO, CH167, CH293) (Ochsenbauer et al., 2012) . SERINC5 reduced the infectivity of all WT HIV-1 by 40%-75%, while nefdefective derivatives of these viruses exhibited an even greater reduction of 85%-93% ( Figure 1B ). In two cases (CH058, STCO1), vpu-and vpr-defective constructs were also slightly more susceptible to SERINC5 inhibition than the WT HIV-1 strains. However, these differences were not significant and most likely due to assay variation. Altogether, only lack of Nef, but not of Vpu or Vpr, significantly reduced infectious virus yield ( Figure 1B, right) . Thus, HIV-1 uses Nef, not Vpu or Vpr, to counteract SERINC5. Figure 1 . Role of Vpu, Vpr, and Nef in the Susceptibility of HIV-1 to SERINC5 and SERINC3 Inhibition (A) HEK293T cells were cotransfected with the indicated WT or nef-defective proviral HIV-1 or SIV constructs and SERINC5 or SERINC3 expression or control plasmid. Shown are the mean levels of infectious virus production by the respective IMCs in the presence of transient SERINC5 or SERINC3 expression (±SEM; n = 9) relative to those obtained in cells transfected with the control vector (100%). The results were derived from three independent experiments, each using triplicate infection of TZM-bl cells to determine infectious virus yield. CC, chronic HIV-1 strain; TF, transmitted/founder. p values represent reduction of infectious virus yield by SERINC expression or differences in susceptibility between WT and nef-defective HIV-1 IMCs. *p < 0.05; **p < 0.01; ***p < 0.001. (B) Mean virus yield obtained for the six HIV-1 IMCs and vpu-, vpr-, or nef-defective derivatives thereof. The experiments were performed and the results obtained as described in the legend for (A). See also Figure S1 .
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Antiviral Activity of SERINC5 and Counteraction by Nef Are Largely Species Independent
To determine the conservation of SERINC5 antagonism, we analyzed a set of 88 HIV-1 NL4-3 proviral constructs containing nef genes from all four groups of HIV-1 (M, N, O, and P), five groups of HIV-2 (A, B, F, G, and H), the simian precursors of both of these human viruses (SIVcpz, SIVgor, and SIVsmm), the descendants of SIVs that recombined to generate SIVcpz (SIVgsn/mus/mon and SIVrcm) (Bailes et al., 2003) , and lentiviruses from 18 additional monkey species. The phylogenetic relationships between these highly divergent primate lentiviruses are shown in Figure S2A . Expression of most of these nef alleles has previously been reported Schmö kel et al., 2011; Heigele et al., 2012; Kluge et al., 2014) . SERINC5 coexpression reduced infectivity of the nef-defective control HIV-1 construct 50-fold (Figures 2 and S2B). As expected (Aiken, 1997; Pizzato, 2010) , MLV glycoGag and VSV-G pseudotyping abolished this inhibitory effect. With few exceptions (HIV-2 B, SIVmnd2), all HIV and SIV nef alleles displayed significant activity against human SERINC5 ( Figure 2 ). Western blot analyses of AU1-tagged forms of Nefs confirmed that proteins lacking anti-SERINC5 activity were nonetheless efficiently expressed (Figure S2C) . Notably, highly divergent nef alleles from various monkey SIVs were as active against human SERINC5 as nef genes obtained from viruses infecting humans or African great apes. Furthermore, nef genes derived from the ape (SIVcpz, SIVgor) and monkey (SIVsmm) precursors did not display higher activity against human SERINC5 than those obtained from SIVs that have not been found in humans.
To avoid overexpression artifacts due to the potent reduction of HIV-1 infectivity by SERINC5, we used the pBJ6 vector in our experiments, which expresses about 100-fold less SERINC5 than HEK293T cells were cotransfected with recombinant HIV-1 NL4-3 proviral constructs containing the indicated nef alleles (3 mg) and an empty control or SERINC5 expression vector (2.5 mg). For control, a glycoGag expression vector was cotransfected with the nef-defective (nef-) NL4-3 construct or the virions were produced in the presence of the VSV glycoprotein (VSV-G). Viral supernatants were obtained 2 days later and used to determine the quantity of infectious HIV-1 in the culture supernatants by infecting TZM-bl indicator cells. Shown are average values ± SD (n = 3) of infectious virion yield relative to those obtained in the absence of SERINC5 expression vector (100%). Results in (A) and (B) were derived from three independent experiments each using triplicate infection. The arrows indicate cross-species transmissions and the recombination event.
(B) Infectious virus yield in Jurkat T cells compared with a derivative thereof lacking SERINC5/3 expression (100%). Parental and SERINC5/3 knockout Jurkat T cells were transduced with HIV-1 NL4-3 proviral constructs containing the indicated nef alleles and infectious virus yield was determined by triplicate infection of TZM-bl cells 3 days later. SERINC5/3 expression and the presence of intact nef genes had no significant effect on p24 antigen production. (C) Correlation between the infectious yield of HIV-1 nef recombinants in the presence of endogenous SERINC5/3 in Jurkat T cells and transiently expressed SERINC5 in HEK293T cells. See also Figure S2 .
regular CMV promoter-driven expression plasmids (Rosa et al., 2015) . Moreover, we also examined the infectious virus yield of 32 HIV-1 NL4-3 constructs containing a broad spectrum of primate lentiviral nef alleles in Jurkat T cells and a derivative thereof lacking SERINC5/3 expression. Endogenous SERINC5/3 reduced nef-defective infectious HIV-1 yield by 33-fold ( Figure 2B ) but had no significant effect on p24 antigen production (data not shown). Most primate lentiviral nef alleles enhanced infectious virus yield in the presence of endogenous SERINC5 expression ( Figure 2B ), and those that counteracted transiently expressed SERINC5 in HEK293T cells were also active against endogenously expressed SERINC5 in Jurkat T cells ( Figure 2C ).
To determine whether the antiretroviral activity is evolutionarily conserved, we analyzed seven different SERINC5 orthologs, from humans (HUM), chimpanzees/gorillas (CPZ/GOR), rhesus macaques/sooty mangabeys (MAC/SMM), African green monkeys (AGM), common marmosets (MAR), tamarins (TAM) and mice (MUR). Consistent with their high degree of sequence conservation ( Figure S3 ), all of them reduced the infectivity of the nef-defective HIV-1 control construct by about 2 orders of magnitude ( Figure 3A ). This was true for all primate derived SERINC5 proteins as well as the SERINC5 ortholog derived from mice. Moreover, 21 nef alleles from highly divergent HIV and SIV strains antagonized all of these SERINC5 orthologs, indicating that this counteraction is largely species independent. However, the efficiency with which the different nef alleles counteracted the various SERINC5 proteins differed considerably. For example, HIV-1 O, SIVcpz, SIVmac, and SIVsmm Nefs, as well as MLV glyco-Gag, restored viral infectivity almost completely, whereas SIVrcm, SIVmus, and HIV-2 B Nefs were much less potent ( Figure 3A ). Importantly, these varying efficiencies were observed for all SERINC5 proteins irrespective of the species origin. For example, the SIVrcm Nef protein was poorly active against human, ape, and three monkeyderived SERINC5 proteins. In contrast, SIVmac Nef counteracted not only its cognate, but also ape, human, and other monkey SERINC5s with great efficiency. In general, levels of infectious virus correlated well between different SERINC5 orthologs ( Figure 3B ), indicating that the antiretroviral activity of SERINC5 is conserved from mice to men and that the varying potency of the different Nefs in antagonizing monkey, ape, and human SERINC5 is largely species independent. Only murine SERINC5 was slightly less effective than primate SERINC5 at reducing viral infectivity and/or more susceptible to Nef-mediated counteraction ( Figure 3C ).
Antagonism of Human SERINC5 by HIV-1 and Its Primate Precursors
To determine whether the anti-SERINC5 activity of Nef may have changed after the cross-species transmissions that preceded the emergence of HIV-1, we analyzed a set of 57 nef alleles from the four groups of HIV-1 and their respective primate precursors. Two groups of HIV-1 (M and N) originated from SIVcpzPtt infecting central chimpanzees (Pan troglodytes troglodytes), whereas groups O and P originated from SIVgor found in western lowland gorillas (Gorilla gorilla gorilla) (Sharp and Hahn, 2011; D'arc et al., 2015) . Eastern chimpanzees (P. t. schweinfurthii) are also infected with SIVcpz but have not transmitted their virus (SIVcpzPts) to humans. SIVcpz arose from a recombination of ancestors of today's SIVgsn/mus/mon infecting Cercopithecus monkeys and SIVrcm from red-capped mangabeys (Bailes et al., 2003) . We found that HIV-1 group M, N, and P Nefs do not differ significantly in their anti-SERINC5 activities ( Figures  4A and S4A ). HIV-1 group O Nefs were more active against human SERINC5 than Nef proteins from the other three HIV-1 groups ( Figure 4A ), although they exhibited a similar ability to downmodulate CD4 or MHC-I ( Figure S4B ). Functional analysis of the Nef proteins of previously inferred most recent common ancestors (MRCAs) of group M, N, and O viruses (Kluge et al., 2014) suggests that HIV-1 group O already possessed high anti-SERINC5 activity prior to its spread in the human population ( Figure 4B ). Human SERINC5 was potently counteracted by all A B C Figure 3 . Antiretroviral Activity of SERINC5 and Nef-Mediated Counteraction Are Conserved and Species Independent (A) Inhibition of HIV-1 NL4-3 constructs containing the indicated nef alleles by SERINC5 orthologs from different primate species or mice. HEK293T cells were cotransfected with recombinant HIV-1 proviral vector and a control plasmid or vectors expressing SERINC5 from the indicated species. Viral supernatants were obtained and infectious HIV-1 production in the culture supernatants was determined as described in the legend to SIVcpz Nef proteins (Figures 3 and 4A), indicating that this antiviral factor does not represent a barrier for cross-species transmission. Interestingly, however, SIVcpzPtt Nef proteins were significantly more active against human and ape SERINC5 than those of SIVrcm (Figures 3 and 4A ), which gave rise to the SIVcpz nef gene . Nefs derived from SIVgsn, SIVmus, and SIVmon whose common ancestor recombined with SIVrcm to become SIVcpz, also displayed poor activity against the human, ape and monkey orthologs of SERINC5 (Figures 3 and 4A ). Thus, Nef gained anti-SERINC5 activity after transmission of SIVs from monkeys to chimpanzees.
Determinants of Anti-SERINC5 Activity in HIV-1 M Nef
To define domains in HIV-1 Nef involved in SERINC5 antagonism, we examined 21 mutants of the highly active primary HIV-1 NA7 nef allele (Greenberg et al., 1997) . Expression and functional analyses of these Nef proteins have previously been reported . We found that mutation of R77A, T80A, and ENNS160AGGG as well as a premature stop at codon 197 significantly reduced Nef's ability to counteract SERINC5 ( Figure 4C ). In contrast, mutations in the acidic region, the first two proline residues in the PxxP [3] domain, the RR PAK2 interac-tion site, and a putative b-COP binding site had no significant disruptive effect. Mutation of three charged C-terminal residues (ERE177AAA) in the C loop disrupted the effect of Nef on SERINC5 inhibition as severely as mutation of the ExxxLL motif ( Figure 4C ). These charged residues, which are critical for CD4 downmodulation and infectivity enhancement, but not MHC-I downmodulation , are located in the C loop of Nef and directly interact with both AP-2 a and s2 (Ren et al., 2014 ; Figure 4D ). These results are in agreement with the previous finding that SERINC5 antagonism requires the interaction of Nef with AP-2 clathrin adaptor complexes (Rosa et al., 2015; Usami et al., 2015) but identify three additional amino acids in the C-terminal loop of HIV-1 Nef as key determinants of its ability to antagonize SERINC5.
Changes in O-Nef Residues that Confer Anti-tetherin Activity Enhance SERINC5 Antagonism To dissect the mechanism(s) responsible for the higher anti-SERINC5 activity of group O Nefs ( Figure 4A ), we analyzed the impact of variable residues (x) in the otherwise highly conserved dileucine-based sorting signal (ExxxLL) (Kluge et al., 2014) .
(C) Activity of NA7 Nef mutants against SERINC5 inhibition. HEK293T cells were cotransfected with NL4-3 proviral constructs containing the indicated nef alleles (3 mg) and an empty control or SERINC5 expression vector (2.5 mg). Viral supernatants were obtained 2 days later and used to quantify infectious HIV-1 in the culture supernatants by infecting TZM-bl indicator cells. Shown are mean values (±SEM) derived from three experiments. (D) Localization of amino acid residues involved in anti-SERINC5 activity in HIV-1 Nef complexed with the a and s2 subunits of AP-2 (Ren et al., 2014) . The ExxxLL (yellow) and ERE (green) motifs in the C loop (red) of Nef are critical for SERINC5 antagonism. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4 . those of M and N viruses, were critical for the acquisition of activity against human tetherin (Kluge et al., 2014) . To determine their role in anti-SERINC5 activity, we compared the susceptibility of HIV-1 NL4-3 constructs expressing WT or NTS 161-163 mutant HIV-1 O and SIVgor Nefs ( Figure 5A ) to this antiviral factor. Amino acid substitutions to NTS, a motif commonly found in group M Nefs, generally reduced the ability of Nef to antagonize SERINC5 ( Figure 5B ), although they did not significantly affect Nef expression levels or downmodulation of CD4 or MHC-I (Kluge et al., 2014) . Thus, alterations in the variable residues of the ExxxLL motif of O-Nefs that conferred activity against human tetherin also increased their potency in SERINC5 antagonism.
SIVcol Nef Counteracts SERINC5 Independently of an ExxxLL AP-2-Binding Motif
It has been shown that the ExxxLL motif in the C-terminal loop is critical for the ability of HIV-1 NL4-3 Nef to antagonize SERINC5 (Rosa et al., 2015) . To determine whether this motif is required for anti-SERINC5 activity of other primate lentiviral Nef proteins, we mutated the leucine residues in the ExxxLL motifs of HIV-1 NA7, SIVmac, SIVagm, SIVblu, SIVdeb, SIVsun, SIVgsn, and SIVcol Nefs to alanines ( Figure 5C ). In most cases, these mutations disrupted the ability of Nef to counteract SERINC5 ( Figure 5D ) as well as to downmodulate CD4 ( Figure S5A ) but had no significant effect or even increased the potency of MHC-I downmodulation ( Figure S5B ). The single exception was the Nef protein of SIVcol from black-and-white colobus monkeys. This virus, which expresses a highly divergent Nef protein ( Figure S2A ) that contains a YxxxLL instead of the canonical ExxxLL motif, antagonized SERINC5 with high efficiency irrespective of the dileucine motif ( Figure 5D ). The SIVcol CGU1 Nef is known to have unusual functional properties because it increases virion infectivity and downmodulates CXCR4 with high efficacy but does not modulate CD4 and MHC-I ( Figure S5 ; Wildum et al., 2006) . We confirmed these properties for SIVcol Nefs from two additional colobus monkeys and showed that they are not just the result of species-specific differences in cellular receptors (data not shown). Thus, the ExxxLL sorting motif in the C loop that recruits AP-2 is critical for the anti-SERINC5 activity of most primate lentiviral Nef proteins, but not the divergent SIVcol Nef, which appears to have evolved different interactions to counteract this antiviral factor.
Most HIV-2 Nef Proteins Are Poor Antagonists of Human SERINC5 Our initial analyses of five HIV-2 nef alleles suggested that they might be less active against SERINC5 than those of HIV-1 and SIVsmm strains infecting sooty mangabeys (Figure 2) , the original host of HIV-2. To follow up on this observation, we analyzed 14 different HIV-2 Nefs. Only two nef alleles (BEN, RH2-1-A8) from the A group of HIV-2, which accounts for the majority of HIV-2 infections (Campbell-Yesufu and Gandhi, 2011) , showed relatively high activity against human SERINC5 ( Figures 6A and  S6A) . Thus, a strikingly high percentage (86%) of HIV-2 Nefs displayed little activity against human SERINC5. Overall, HIV-2 Nefs were almost 10-fold less potent than SIVsmm Nefs ( Figure 6A ) and 5-fold less potent than HIV-1 Nefs ( Figure 6B ), although most of them efficiently downmodulated CD4 and MHC-I ( Figure S6B ).
Nef-Mediated Anti-SERINC5 Activity Correlates with SIV Prevalence Rates in the Wild
The higher anti-SERINC5 activity of HIV-1 nef alleles compared with those obtained from HIV-2 strains ( Figure 6 ) suggested a potential role of this restriction factor in viral spread. To test this hypothesis, we examined whether the magnitude of Nefmediated SERINC5 antagonism correlates with the prevalence of different SIVs in their respective natural hosts. A review of published SIV prevalence data identified 16 monkey species for which more than ten samples (average 200) had previously been screened for SIV and for which functional nef alleles were also available (Table S1 ). Together with non-invasive screening results of wild-living chimpanzees and gorillas, infection rates and Nef-mediated SERINC5 antagonism data were available for 19 different SIV strains ( Figure 7A ).
To determine whether there is an association between viral prevalence and the strength of Nef-mediated SERINC counteraction, we performed correlation analyses using phylogenetically independent contrasts (Felsenstein, 1985) , which transforms comparative data to account for covariation of phenotypes due to an underlying shared ancestry. Using data from all 19 SIVs ( Figure 7B ), we found a significant correlation between the ability of a given SIV Nef to counteract SERINC5 and the prevalence of the corresponding virus in its natural host species (R 2 = 0.1872, p = 0.0377) ( Figure 7B, top) . Thus, Nef-mediated anti-SERINC activity may explain about 19% of the variation in SIV prevalence among the different primate species. Because monkey and great ape-derived SIVs differ in their evolutionary history, with the ape SIVs representing more recent monkey SIV recombinants (Bailes et al., 2003) , we also examined these two groups separately. Although SIV infection rates in apes are lower and more variable than those in most monkey species (Keele et al., 2006; Van Heuverswyn et al., 2007; Li et al., 2012; D'arc et al., 2015) , SIVcpz is more prevalent in eastern than in central chimpanzees, and both SIVcpzPtt and SIVcpzPts are more common in chimpanzees than SIVgor is in western lowland gorillas ( Figure 7B , middle; Table S1 ). Again, there was an association between prevalence rates of SIVcpzPts, SIVcpzPtt, and SIVgor and the potency of their respective Nef proteins in counteracting SERINC5 (Figure 7B, middle) . However, the small number of ape SIVs studied precluded a meaningful statistical analysis. Interestingly, when the correlation analysis was restricted to the 16 monkey SIVs, the relationship between percent prevalence and viral infectivity was slightly more significant (R 2 = 0.2644, p = 0.0233; Figure 7B , bottom), consistent with the longstanding relationship of monkey SIVs and their respective hosts. A similar level of significance was found when the Nef protein of SIVcol, which is an effective SERINC5 antagonist but lacks the otherwise conserved CD4 and MHC-I functions, was excluded (adjusted R 2 = 0.2894, p = 0.0250).
DISCUSSION
In this study, we examined the ability of primate lentiviral Nef proteins to counteract the antiviral restriction factor SERINC5. We show that this Nef function is highly conserved among all primate lentiviral lineages ( Figure 2 ) and largely independent of the species origin of the SERINC5 ortholog ( Figure 3 ). However, some interesting differences were also identified. First, all nef alleles from SIVs, whose ancestors recombined to generate SIVcpz (i.e., SIVgsn/mus/mon and SIVrcm), were poorly active against monkey, ape, and human SERINC5 orthologs (Figure 2) . Because SIVcpz Nefs are generally highly effective antagonists of SERINC5, it seems clear that some mutations that increased anti-SERINC5 activity were selected for during viral adaptation to chimpanzees. Second, we found that HIV-1 Nefs are substantially more potent antagonists of SERINC5 than HIV-2 Nef proteins ( Figure 4B ). Because SIVsmm Nefs are also highly active against SERINC5, HIV-2 Nefs may have partly lost this function following the transfer to humans. Third, we found a significant, phylogenetically corrected correlation between the A B Figure 6 . SERINC5 Counteraction by nef Alleles from HIV-2 and Its Simian Precursors (A) Effect of nef alleles from HIV-2 and its simian SIVsmm counterparts on HIV-1 inhibition by human SERINC5. Each symbol represents the average infectious virus yield obtained for HIV-1 NL4-3 containing nef alleles from the indicated primate lentiviruses in the presence of human SERINC5 relative to the vector control (100%). Values were derived from at least three experiments and shown means ± SEM. (B) Activities of nef alleles from HIV-2 and HIV-1. Shown are minimum and maximum values, 25% and 75% percentiles, and median values. See also Figure S6 . potency of Nef-mediated SERINC5 counteraction and the prevalence rates of the corresponding SIVs in great apes and African monkey species (Figure 7) . Thus, high-level SERINC5 antagonism resulting in increased virion infectivity seems to affect the ability of primate lentiviruses to spread within their host species. Previously identified restriction factors represent barriers to primate lentiviral cross-species transmission because they are counteracted (or evaded) in a species-specific manner (Pyndiah et al., 2015) . One well-known example is tetherin antagonism (or lack thereof) by the four groups of HIV-1. Human tetherin contains a deletion conferring resistance to the Nef protein used by most SIVs to counteract this restriction factor (Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009 ). To counteract tetherin in humans, the M group of HIV-1 switched to Vpu , while group O strains acquired the ability to target a different region in Nef (Kluge et al., 2014) . Vpu proteins of rare group N HIV-1 strains are still evolving toward higher antitetherin activity , and HIV-1 group P has not yet acquired an effective tetherin antagonist Yang et al., 2011) . Thus, suboptimal viral adaptation following cross-species transmission may limit viral spread. In contrast to tetherin antagonism, however, SERINC5 counteraction is not host specific (Figure 3 ). Orthologs derived from monkeys, apes and humans exhibit very similar antiretroviral activity as well as susceptibility to Nef-mediated antagonism (Figure 3 ), suggesting that SERINC5 does not usually pose a barrier to cross-species transmission. Nonetheless, we identified substantial differences in the anti-SERINC5 activity of Nef proteins from different HIV/SIV lineages that are independent of the species origin of SERINC5 and may be the result of balancing different functions. Nef performs an enormous number of activities, and it is likely that the necessity to maintain multiple func-tions comes at a cost for some of them. For example, it has been shown that nef alleles obtained after AIDS progression are highly active in downregulation of CD4 and enhancement of HIV-1 infectivity but do not efficiently downmodulate MHC-I (Carl et al., 2001) .
The finding of a significant correlation between the extent of Nef-mediated SERINC5 antagonism and the prevalence of the corresponding SIVs in their respective host species came as a surprise (Figure 7 ). SIV prevalence rates depend on many viral and non-viral factors, including population structure, transmission dynamics, host genetics, and immune responses. Although we analyzed more than 100 Nef proteins and included only those that were functionally active in at least one assay in addition to SERINC5 antagonism (Table S1 ), only single Nef proteins were available for analysis for some SIV strains. Moreover, the prevalence estimates in Table S1 can only serve as a very rough approximation, because the extent to which some primate species were sampled was very limited. Despite these limitations, the significant correlation, which was phylogenetically corrected, indicates that a considerable fraction (19%-26%) of the variation in SIV prevalence among the different primate species can potentially be explained by the strength of their Nefmediated anti-SERINC activity. Notably, the prevalence rates of the four groups of HIV-1 did not correlate with the efficiency of SERINC5 antagonism, which is likely because HIV-1 is the result of very recent zoonotic transmissions. There are clear differences in the extent of adaptation of the four different HIV-1 groups to the human host Sharp and Hahn, 2011) , and the spread of HIV-1 in humans is affected by many factors that do not apply to the spread of SIV in the wild. Thus, the HIV-1 data do not argue against a relationship between SIV prevalence and SERINC5 antagonism in wild-living primates. Figure 7 . Relationships between the Potency of Nef-Mediated SERINC5 Antagonism and SIV Prevalence Rates (A) Evolutionary relationships of the SIV strains included in the correlation analyses (B) based on Nef protein sequences (a maximum likelihood tree based on Pol protein sequences is shown in Figure S2 ). (B) Relationships between the prevalence rates of SIVs infecting wild-living ape and monkey species and the average infectious yield of viruses expressing the corresponding Nef proteins in the presence of SERINC5 relative to the vector control (100%). Shown are results for 19 different SIV lineages for which functionally active nef alleles were available (top), for SIVcpzPts, SIVcpzPtt, and SIVgor infecting great apes (middle), and for SIVs infecting 16 African monkey species (bottom). The correlation analyses were performed using independent contrasts to correct for the underlying Nef phylogeny (A) and yielded significant values both for the 19 (top: R 2 = 0.1872, p = 0.0377) and 16 (bottom: R 2 = 0.2644, p = 0.0233) SIV panels. The SIVcol strain (indicated in red) expresses an unusual Nef protein that antagonizes SERINC5 but lacks other Nef functions. The numbers of nef alleles analyzed and number of apes and monkeys examined for SIV are shown in Table S1 .
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Our finding that the majority of HIV-2 Nefs are less potent against SERINC5 than those of HIV-1 is in agreement with the previous observation that the latter are more effective in enhancing viral infectivity and replication (Mü nch et al., 2007) . This is despite the fact that HIV-2 Nefs potently downmodulate CD3 and CD28 and are as effective as HIV-1 Nefs in modulating MHC-I (Mü nch et al., 2005; Schindler et al., 2006) . Thus, the poor anti-SERINC5 activity of HIV-2 Nefs is not just the result of reduced expression levels or generally impaired function. In contrast, Nef proteins derived from SIVsmm (the direct precursor of HIV-2) are potent antagonists of human and simian SERINC5 proteins (Figure 3) . SIVsmm Nefs are also highly active in other functions, such as modulation of CD4, CD3, CD28, or TCR-CD3 (Schmö kel et al., 2009) . Although HIV-2 Nef seems to have lost efficient anti-SERINC5 activity, it is possible that another HIV-2 protein may have acquired this function. One candidate is Env, which has been shown to confer SERINC5 resistance independently of Nef function in HIV-1 (Usami and Gö ttlinger, 2013) .
Nef is one of the most variable proteins of primate lentiviruses, and some HIV and SIV Nefs show only 30% sequence identity at the amino acid level. Nonetheless, the dileucine-based sorting motif [E/D]xxxLf is conserved among the great majority of primate lentiviruses. Our data show that this motif is required for SERINC5 antagonism by HIV-1 and most SIVs but also identified an interesting exception. The SIVcol Nef is highly active against SERINC5 despite the absence of a canonical [E/D]xxxLf motif. This Nef protein is functionally and structurally different from all other SIV Nefs and lacks otherwise common activities, such as modulation of CD3, CD4, and MHC-I, although it is highly active in downmodulation of CXCR4. Thus, the SIVcol Nef may have evolved differently, and potent SERINC5 antagonism may represent an example of convergent evolution. We also identified three adjacent residues (ERE) in the C loop of HIV-1 Nef that are involved in AP-2 interaction and seem critical for SERINC5 antagonism (Figures 4C and 4D ). Finally, we found that alterations in the variable residues of the ExxxLL motif that confer anti-tetherin activity to HIV-1 group O strains (Kluge et al., 2014) also significantly enhanced the efficiency of SERINC5 antagonism ( Figure 5 ). Nef interacts with different adaptor proteins to modulate endocytosis as well as anterograde transport of cellular proteins (Roeth and Collins, 2006) . Thus, further studies are required to determine, which Nef interactions besides AP-2 recruitment may be modulated by the alterations in the C-loop that affect Nef-mediated SERINC5 and tetherin antagonism.
In summary, we show that essentially all primate lentiviral Nef proteins antagonize SERINC5 in a largely species-independent manner but with different efficiencies. Nef seems to have acquired enhanced anti-SERINC5 activity after the cross-species transmission from monkeys to apes and from apes to humans. The significant correlation between the prevalence of SIVs and the ability of their Nefs to counteract SERINC5 supports a role of this restriction factor in the transmissibility of primate lentiviruses. It will be important to define the structural determinants in Nef involved in SERINC5 antagonism to selectively disrupt this activity and to determine its relevance for viral replication, pathogenesis, and transmission in vivo.
EXPERIMENTAL PROCEDURES Expression Vectors
The pBJ6-SERINC5-HA as well as the pBJ5-MLV glycoGag 189-HA expression vectors have been described (Rosa et al., 2015) . SERINC5 orthologs from other species were amplified from cDNA and compared with published sequences. For details, see Supplemental Experimental Procedures. Cloning of Nef mutants into the bi-cistronic CMV-based pCG expression vector coexpressing the GFP was essentially performed as described previously (Kluge et al., 2014) . The pCG control vector expressing only eGFP (eGFP control) contains an NL4-3 nef gene with a mutation in the initiation codon and two premature stop codons at positions 3 and 40 of the reading frame. All PCR-derived inserts were sequenced to confirm their accuracy.
Proviral Constructs
Generation of HIV-1 (NL4-3-based) proviral constructs carrying functional nef genes followed by an IRES element and the eGFP gene has been described previously . See Supplemental Experimental Procedures for details and generation of additional proviral HIV-1 and SIV constructs.
Cell Culture and Transfections
Cells were cultured and transfected or infected as described in Supplemental Experimental Procedures.
SERINC5/3 Knockout Jurkat Cells SERINC5 and SERINC3 were knocked out sequentially in Jurkat Tag cells by targeting two different exons of each gene using CRISPR/Cas9 as described in Supplemental Experimental Procedures.
Virus Yield and Infectivity Assays
Virus yield and infectivity assay were conducted in principle as described (Mü nch et al., 2007; Zhang et al., 2009) . For details, see Supplemental Experimental Procedures.
Virus Stocks and Transduction
HEK293T cells were transfected with HIV-1 (NL4-3) constructs coexpressing Nef and eGFP by the calcium phosphate method as described previously (Mü nch et al., 2007) . Prestimulated CD4+ T cells were transduced as described in Supplemental Experimental Procedures.
Flow Cytometric Analysis
To determine the Nef-mediated down-modulation of CD4 and MHC-I from the surface of infected cells, CD4+ T cells were transduced with HIV-1 (NL4-3) constructs coexpressing Nef and eGFP. Three days post-transduction, receptor expression was examined by fluorescence-activated cell sorting analysis in GFP+ cells as described previously . See Supplemental Experimental Procedures for details.
Western Blot AU-1-tagged Nef proteins were generated and analyzed as described previously . For details, see Supplemental Experimental Procedures.
Sequence Analyses and Accession Numbers SERINC5 protein sequences were aligned using Multalign, followed by some manual editing. GenBank accession numbers for SERINC5 and Nef sequences utilized in this paper are provided in the Supplemental Information.
Structural Analysis of Nef Protein structures are based on a complex of NL4-3 Nef with the a and s2 subunits of AP-2 (Protein Data Bank accession number 4NEE) and were displayed with CLC Main Workbench 7.
Statistical Analysis
Statistical calculations and group comparisons were performed using a twotailed Student's t test implemented in the Prism package version 4.0 (Abacus Concepts). p values < 0.05 were considered to indicate statistical significance. Correlations were calculated with the linear regression module. The method of phylogenetically independent contrasts (Felsenstein, 1985) , implemented in the R package Analysis of Phylogenetics and Evolution (Paradis et al., 2004) , was used to assess the relationship of SIV prevalence rates to viral infectivity using the phylogenetic relationships of the corresponding Nef amino acid sequences to correct for the underlying shared ancestry. Because phylogenetically independent contrast values have an expected mean of zero, linear regressions were constrained to go through the origin (Garland et al., 1992) .
ACCESSION NUMBERS
The GenBank accession numbers for the SERINC5 and Nef sequence data reported in this paper are included in the Supplemental Information. (Pizzato et al., 2010; Rosa et al., 2015) . SERINC5 alleles from chimpanzees, African green monkeys, rhesus macaques and tamarins were amplified from cDNA prepared from PBMCs of these species and kindly provided by Amalio Telenti (San Diego). The amino acid SERINC5 sequence of sooty mangabeys (GenBank: XM_012089186) is identical to the long isoform derived from rhesus macaque cDNA ( Figure S3 ). Murine SERINC5 was amplified from cDNA derived from the 3T3 mouse cell line. All PCR-derived SERINC5 sequences were confirmed by comparison with published sequences. Only the isolated African green monkey SERINC5 contained one substitution (E364D) in three independent clones compared to the published sequence. A construct encoding the amino acid sequence of the whitetufted-ear marmoset (Callithrix jacchus) (GenBank: XM_008991895) was generated by site directed mutagenesis of the tamarin SERINC5 expression construct. All amplified SERINC5 genes contained the same HA-tag and were cloned in the pBJ6 vector via the NotI and BspEI restriction sites and confirmed by sequence analysis.
Nef expression constructs. Cloning of nef alleles in bi-cistronic CMV-based pCG expression vector coexpressing the green fluorescent protein (eGFP) was performed as described previously (Schindler et al., 2006; Sauter et al., 2009) . In brief, nef alleles were PCR-amplified using primers introducing XbaI and MluI restriction sites flanking the nef reading frame, which were then used to insert the full nef sequence into the restriction site of the vector. Furthermore, some the nef alleles of SIVrcm8081, SIVrcmNg411, SIVagi, SIVdrlD5, SIVmnd1GB1, SIVmnd2-5440, SIVsunL14 and SIVmus3Pts02 were chemically synthesized based on published data (accession numbers are provided below) and cloned in the pCG vector and proviral NL4-3 constructs. Correctness of all constructs was confirmed by sequence analysis.
Novel HIV-1 clones. Generation of NL4-3, CH058, CH077, CH167, CH198, CH293 and ZM246 HIV-1 infectious molecular clones has been previously described (Adachi et al., 1986; Ochsenbauer et al., 2012; Parrish et al., 2013) . To generate vpr-defective IMCs of CH058 and ZM246 the ATG start-codon was mutated GTG. The vpr-defective IMC of TF (CH198) and CC (STCO, CH167, CH293) viruses were generated by introducing two stop-codons in vpr-frame after the stop-codon of vif with the help of the QuikChange II XL® Site-Directed Mutagenesis Kit (Agilent Technologies). The same method was used to generate vpu-defective IMCs. Here two stop-codons were introduced directly after the startcodon of vpu. Additionally the nef-defective IMCs of CH058, STCO, CH293 and ZM246 were generated in the same way. For the nef-defective IMCs of CH167, CH077 and CH198 splice overlap extension (SOE) PCR was used to introduce two stop-codons directly after the start-codon of nef. The PCR-fragments were replaced in the IMCs via unique restriction sites (AleI + NotI for CH167, StuI + Bsu36I for CH198 and the double cutter BSu36I for CH077). The second start codon in the nef allele of CH077 at codon-position 17 was replaced by a stop-codon in the same SOE PCR. All modifications in the IMCs and the absence of undesired changes were confirmed by sequence analysis. Proviral constructs. Generation of HIV-1 (NL4-3 based) proviral constructs encoding various primate lentiviral nef genes followed by an IRES element and the eGFP gene has been described previously . In brief, splice overlap extension (SOE) PCR was used to replace the NL4-3 nef allele with nef genes from various HIV-1, HIV-2 and SIV stains via the unique HpaI and MluI restriction sites. For MHC-I and CD4 receptor downmodulation experiments different nef alleles were introduced into a vpu-and env-defective pBR_NL4-3 backbone. The proviral HIV-1 constructs are replicationcompetent and express all viral genes, including nef via the regular LTR promoter and splice sites. The integrity of all PCR-derived inserts was confirmed by sequence analysis. The nef-defective HIV-1 NL4-3 construct (nef-) contains premature stop codons at positions 3 and 40 as well as a mutation in the ATG initiation codon.
Cell culture and transfections. HEK293T cells were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% FCS plus 2 mM glutamine, 100 units/ml penicillin and 100µg/ml streptomycin and transfected by the calcium phosphate method as described previously (Munch et al., 2007) . TZM-bl cells were kindly provided by Drs. Kappes and Wu and Tranzyme Inc. through the NIH AIDS Reagent Program and were kept in DMEM supplemented with 10% FCS plus 2 mM glutamine.
TZM-bl cells express CD4, CCR5 and CXCR4 and contain the ß-galactosidase genes under the control of the HIV-1 promoter (Derdeyn et al., 2000; Platt et al., 1998; Wei et al., 2002) . CD4+ T cells from healthy human donors were isolated using human CD4+ T cell RosetteSep kit (Stemcell Technologies) following the protocols provided by the manufacturer. The cells were stimulated for 3 days with human CD3/CD28 T-Activator Dynabeads (Invitrogen) at a cell-to-bead ratio of 1:1 and with 10 ng/ml interleukin-2 (IL-2) prior to transduction.
Virus yield and infectivity assays.
To determine the effect of Nef in trans, HEK293T cells were seeded in six-well plates and transfected with 2.5 μg of the HIV-1 NL4-3 nef-GFP reporter proviral construct, 500 ng Nef and 2.5µg pBJ6-SERINC5-HA expression plasmids or pBJ6-empty vector. As positive control 500 ng HA-tagged MLV glycoGag was transfected in trans instead of Nef. As further control a VSV-G expression construct (0.5 µg) was cotransfected with nef-or wt HIV-1 NL4-3 proviral constructs (3 µg) in the presence or absence of SERINC5-HA (2.5 µg) to generate VSV-G pseudotyped virus particles. To measure Nef-mediated SERINC5 counteraction in cis, HEK293T cells were transfected with 3 µg of HIV-1 NL4-3 GFP reporter proviral constructs containing various nef alleles and 2.5 µg pBJ6-SERINC5-HA expression plasmid or pBJ6-empty vector. At two days post-transfection supernatants were harvested and analyzed for infectious HIV-1 yield by a 96-well TZM-bl infection assay as described (Munch et al., 2007) .
Virus stocks and transduction.
To generate viral stocks, HEK293T cells were cotransfected with the proviral HIV-1 constructs and a plasmid (pHIT-G) expressing VSV-G to achieve comparably high initial infection levels for flow cytometric analysis. The medium was changed after overnight incubation, and virus was harvested 24 h later. Prestimulated CD4+ T cells were transduced with NL4-3-based proviral constructs coexpressing the various Nef proteins and eGFP as described previously . For the detection of CD4 downmodulation, vpu-and env-defective proviral HIV-1 constructs were used, since both gene products also reduce CD4 cell surface expression and thus mask the effect of Nef. Flow cytometric analysis was performed at 3 days post-transduction. SERINC5/3 knock-out Jurkat cells. Knock outs were generated using CRISPR/Cas9. Jurkat Tag cells were electroporated with two pSpCas9(BB)-2A-GFP vectors (PX458, a gift from Feng Zhang, Addgene plasmid # 48138) (50) containing gRNA sequences targeting two different exons of SERINC5 or SERINC3, followed by FACS sorting based on high GFP expression. Single cell derived clones were expanded and a clone was selected after verifying the presence of the expected deletion by PCR. SERINC5 and SERINC3 were knocked-out sequentially using the same procedure. The following gRNA sequences were used: 5'-GCTGAGGGACTGCCGAATCC-3' and 5'-GGCGTACCACAGCTT-GTTAC-3' for SERINC5, 5'-ATAAATGAGGCGAGTCACCG-3' and 5'-CTCCGAGCGGCAGTAC-ACAA-3' for SERINC3.
Flow cytometric analysis. CD4-APC (BD Biosciences, 555349) and MHC-I-PE (Dako, R7000) expression in purified human CD4+ T cells transduced with HIV-1 (NL4-3) constructs coexpressing Nef and EGFP was measured as described previously . For quantification of Nefmediated modulation of the specific surface molecules, the levels of receptor expression were determined for cells expressing eGFP. The extent of down-modulation (n-fold) was calculated by dividing the mean fluorescence intensity (MFI) obtained for cells transduced with the nef-NL4-3 control viruses by the corresponding values obtained for cells transduced with viruses coexpressing Nef and eGFP. average expression levels (± SEM; n = 3) relative to those obtained in CD4+ T cells infected with the nef-defective HIV-1 NL4-3 IRES-eGFP construct (100%). Please note that HIV-1 NL4-3 construct contained intact vpu and env genes like described in the legend to Figure S4 .
Six supplemental figures
